JP2021512920A5 - - Google Patents

Info

Publication number
JP2021512920A5
JP2021512920A5 JP2020542858A JP2020542858A JP2021512920A5 JP 2021512920 A5 JP2021512920 A5 JP 2021512920A5 JP 2020542858 A JP2020542858 A JP 2020542858A JP 2020542858 A JP2020542858 A JP 2020542858A JP 2021512920 A5 JP2021512920 A5 JP 2021512920A5
Authority
JP
Japan
Prior art keywords
amino
pharmaceutically acceptable
carboxylic acid
acceptable salt
difluoromethylenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512920A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/017201 external-priority patent/WO2019157273A1/en
Publication of JP2021512920A publication Critical patent/JP2021512920A/ja
Publication of JP2021512920A5 publication Critical patent/JP2021512920A5/ja
Pending legal-status Critical Current

Links

JP2020542858A 2018-02-08 2019-02-08 耳鳴、急性感音性難聴、メニエール病、トゥレット症候群、注意欠陥多動性障害、および嗜癖の治療における(1s,3s)−3−アミノ−4−(ジフルオロメチリデン)シクロペンタン−1−カルボン酸および(s)−3−アミノ−4−(ジフルオロメチルエニル)シクロペンタ−1−エン−1−カルボン酸の使用 Pending JP2021512920A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862628020P 2018-02-08 2018-02-08
US62/628,020 2018-02-08
US201862628541P 2018-02-09 2018-02-09
US62/628,541 2018-02-09
PCT/US2019/017201 WO2019157273A1 (en) 2018-02-08 2019-02-08 Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction

Publications (2)

Publication Number Publication Date
JP2021512920A JP2021512920A (ja) 2021-05-20
JP2021512920A5 true JP2021512920A5 (cg-RX-API-DMAC7.html) 2022-02-15

Family

ID=67475310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542858A Pending JP2021512920A (ja) 2018-02-08 2019-02-08 耳鳴、急性感音性難聴、メニエール病、トゥレット症候群、注意欠陥多動性障害、および嗜癖の治療における(1s,3s)−3−アミノ−4−(ジフルオロメチリデン)シクロペンタン−1−カルボン酸および(s)−3−アミノ−4−(ジフルオロメチルエニル)シクロペンタ−1−エン−1−カルボン酸の使用

Country Status (10)

Country Link
US (1) US10653652B2 (cg-RX-API-DMAC7.html)
EP (1) EP3735237A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021512920A (cg-RX-API-DMAC7.html)
KR (3) KR20240154700A (cg-RX-API-DMAC7.html)
CN (1) CN112261938A (cg-RX-API-DMAC7.html)
AU (1) AU2019216742B2 (cg-RX-API-DMAC7.html)
CA (1) CA3090258A1 (cg-RX-API-DMAC7.html)
IL (1) IL276287B1 (cg-RX-API-DMAC7.html)
MX (1) MX2020008359A (cg-RX-API-DMAC7.html)
WO (1) WO2019157273A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX389001B (es) 2015-10-23 2025-03-20 Navitor Pharm Inc Moduladores de interacción de sestrina-gator2 y sus usos.
ES3040534T3 (en) 2017-04-26 2025-11-03 Navitor Pharm Inc Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
US11771671B2 (en) 2018-02-08 2023-10-03 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
AU2019243586A1 (en) * 2018-03-29 2020-10-15 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders
WO2020086816A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
AU2020376950B2 (en) 2019-11-01 2026-06-11 Supernus Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
US12678586B1 (en) 2023-06-12 2026-07-14 John Brundage Noise injury relief system

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
US6656172B1 (en) * 2002-09-27 2003-12-02 Medtronic, Inc. Method for treating severe tinnitus
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
CA2790820A1 (en) 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
US20130230586A1 (en) * 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
WO2013006857A1 (en) 2011-07-07 2013-01-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
ES2862673T3 (es) * 2011-12-12 2021-10-07 Zilentin AG Tratamiento del tinnitus mediante la modulación del cotransportador de cloruro NKCC1 en el sistema auditivo
WO2013112363A1 (en) * 2012-01-27 2013-08-01 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
CN108137484B (zh) * 2015-10-09 2021-02-12 西北大学 作为用于治疗癫痫、成瘾和肝细胞癌的gaba氨基转移酶灭活剂的化合物
KR20240110989A (ko) 2017-02-08 2024-07-16 오비드 테라퓨틱스 인크. 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들

Similar Documents

Publication Publication Date Title
JP2019031502A5 (cg-RX-API-DMAC7.html)
KR101429735B1 (ko) 와우각 흥분독성에 의해 유발된 이명의 치료를 위한 nmda 수용체 길항제의 용도
CN1307998C (zh) 用于局部治疗美尼埃尔氏疾病、耳鸣和/或听力损伤的新方法和组合物
RU2010150863A (ru) Фармацевтическая композиция для лечения ушных заболеваний
JP2009510047A (ja) 蝸牛興奮毒性によって誘導される耳鳴りを処置する方法
JP2023076465A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
JP2017509686A5 (cg-RX-API-DMAC7.html)
JP2011529854A5 (cg-RX-API-DMAC7.html)
JP2008538115A5 (cg-RX-API-DMAC7.html)
JP2019512528A5 (cg-RX-API-DMAC7.html)
JP2013544850A5 (cg-RX-API-DMAC7.html)
JP2004527551A (ja) エナンチオ純粋なエスシタロプラムの使用方法
NZ600478A (en) Beta-carbolines for use in the treatment of hearing loss and vertigo
JP2013523769A5 (cg-RX-API-DMAC7.html)
JP2005508872A5 (cg-RX-API-DMAC7.html)
JP2015522606A5 (cg-RX-API-DMAC7.html)
JP2009517393A (ja) 不安症の治療方法
JP2007509960A5 (cg-RX-API-DMAC7.html)
JP2022506113A5 (cg-RX-API-DMAC7.html)
RU2008127882A (ru) Лечение пищевода барретта
RU2008134143A (ru) Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения
AU2011208939B2 (en) Compounds for use in the treatment of diseases
JP2007505156A5 (cg-RX-API-DMAC7.html)
Suwaki et al. Nasal speaking valve: A device for managing velopharyngeal incompetence 1
JP2010523662A (ja) 睡眠関連呼吸障害を処置するための方法及び組成物